Company Insights

INMB customer relationships

Explore interactive graphBrowse insights index
INMB customer relationship map

INmune Bio (INMB) — customer relationships and what they reveal for investors

INmune Bio is a clinical-stage immunotherapy company that repositions innate immunity to treat cancer, Alzheimer’s disease and NASH. The company currently monetizes by supplying research- and trial-grade biological materials (CORDStrom, MSCs) to third parties, pursuing clinical development programs, and positioning its platform for partnerships or licensing with larger biopharma players. Revenue today is immaterial and episodic, while near-term value for investors comes from clinical progress, collaborator exposure, and the ability to convert research-supply activity into strategic commercial deals. For a concise run-through of these customer signals and their investor implications, visit https://nullexposure.com/.

How INmune’s customers reveal its operating posture

INmune operates as a seller of core research and clinical-stage materials rather than as a commercial-stage therapeutics vendor. The company explicitly states it will "supply CORDStrom to third parties for their research use and in clinical trials," which positions INmune as a supplier to other drug developers and trial sponsors rather than as a downstream commercial distributor. This contracting posture creates a revenue profile that is:

  • Concentrated and episodic — reported sales have been to very few customers and at low absolute amounts.
  • Strategically critical but operationally early — the products being supplied (CORDStrom, MSCs) are central to INmune’s development roadmap but are sold at the research/clinical scale, not at commercial volumes.
  • Financing-driven maturity — the company uses financing tools such as an ATM program to fund operations, indicating an early-stage balance between R&D spending and liquidity management.

The company filing reports sales of MSCs to a single United Kingdom customer with recognized revenues of $155,000 in 2023 and $14,000 in 2024, illustrating the low-dollar, experimental nature of customer revenue. The filing also records that between January 1, 2025 and March 27, 2025 the company sold 649,860 shares through an ATM program for net proceeds of $5.3 million, which frames the company’s near-term cash posture and spend-band: typical transactions and funding rounds fall in the $1M–$10M range.

Customer relationships disclosed in the 2024 filing — what they mean

Below are every customer or external company mentioned in INmune’s FY2024 disclosure, with a plain-English take and the source context.

Gliacure

INmune’s filing notes that Gliacure is pursuing a microglia-targeted small molecule (GC021109) for Alzheimer’s disease, a therapeutic focus that overlaps INmune’s interest in innate immune modulation in neurodegeneration. According to INmune Bio’s 2024 Form 10‑K, this competitor/peer activity is part of the broader Alzheimer’s landscape relevant to INmune’s positioning in CNS immune therapies (FY2024 filing).

Denali Therapeutics (DNLI)

The 10‑K references Denali’s DNL747, which targets signaling proteins in the TNF pathway that control inflammation and cell death — a mechanistic area adjacent to INmune’s innate-immune approaches. Denali’s work demonstrates parallel large‑biotech investment into inflammation and neurodegeneration pathways, cited in INmune’s FY2024 filing.

Eisai (Leqembi / Lecanemab)

INmune’s filing cites Eisai’s Lecanemab (Leqembi) as an approved therapy for Early Alzheimer’s disease (approval noted January 2023), a regulatory and commercial landmark in the AD market that changes competitive dynamics and partner interest. The 10‑K highlights this approval as a contextual market event (FY2024 filing).

Lilly (Donanemab)

The 10‑K references Lilly’s donanemab, described as a third anti-amyloid therapy expected through regulatory milestones around 2Q2024 in the filing; this reflects continued competitive sequencing in Alzheimer’s that impacts trial design, endpoints and potential collaborator strategies for INmune (FY2024 filing).

Strategic read-through for investors

The customer and market mentions in INmune’s filing produce a clear picture: INmune is an upstream supplier and development-stage participant in markets where major biopharma firms are executing first-generation commercial strategies. That creates both risk and optionality.

  • Risk — limited revenue and customer concentration. Sales to a single UK customer and the tiny absolute revenue totals underscore that operating cash flow is not a near-term value driver; the company relies on financing. The ATM proceeds of $5.3M in early 2025 are operationally meaningful relative to its revenue base and indicate a spend-band and cash strategy that investors must monitor closely.
  • Opportunity — relevance to big‑pharma programs. The presence of multiple established Alzheimer’s programs (Eisai, Lilly, Denali) validates the therapeutic axis INmune targets and increases the likelihood that larger companies will seek adjunctive or combinatory immune approaches as their commercial programs mature.
  • Contracting posture and maturity. INmune’s business model is seller-centric for research and clinical materials, and the stage is active but pre-commercial; converting research supply into partnership or licensing revenue is the critical inflection investors should track.
  • Concentration and criticality. Revenue concentration is high, but the supplied products are core to INmune’s development strategy, making each customer relationship operationally more important than its dollar value suggests.

For a structured, customer-centric risk assessment and to track counterparties and contract signals over time, visit https://nullexposure.com/.

What investors should watch next

  • Clinical readouts and enrollment updates that could convert research relationships into development partnerships or licensing agreements.
  • Contracting disclosures that expand beyond single-customer sales — any multi-center trial supply agreements or pharma collaborations would materially change revenue trajectory.
  • Liquidity moves: follow any further ATM activity or equity financing that extends runway beyond the $5.3M reported for Q1 2025.
  • Competitive developments from Eisai, Lilly and Denali that affect endpoint selection, regulatory comparators, and partner interest.

Bottom line and action items

  • INmune is a development-stage supplier and platform company with negligible commercial revenue but clear strategic exposure to the Alzheimer’s and innate-immune treatment markets.
  • Customer revenue today is concentrated, small, and episodic, so valuation is driven by clinical and partnership outcomes rather than current sales.
  • Monitor financing and partnership activity; these are the most immediate levers for value creation or dilution.

If you want a tailored view of customer relationships and counterparty risk for early-stage biotech investments, explore our coverage and tools at https://nullexposure.com/. For ongoing tracking of INMB counterparties and contract signals, bookmark https://nullexposure.com/ and check back as filings and clinical disclosures evolve.